Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2013

View Archived Issues

Dalesconol B exerts neuroprotective effects, attenuates memory deficits in models of Alzheimer's

A novel glycooptimized biobetter of cetuximab is well tolerated in first-in-human trials

Research gives insight into miR-17-5p's role in the pathogenesis of pediatric SLE

Oncodesign's IMODI project wins award from French government

Anti-osteopontin antibodies as a new therapeutic approach to MS

Volociximab administered with ranibizumab in phase I/II trial

Targeting DNA repair with ATX-101 for enhancing sensitivity to anticancer drugs

AMAG Pharmaceuticals reports preliminary data from ferumoxytol extension study

Diffusion Pharmaceuticals completes enrollment in phase II trans-sodium crocetinate trial

LDK-378 receives FDA breakthrough therapy designation for NSCLC

Omni Bio Pharmaceutical reports preclinical results for Fc-AAT

Ocriplasmin approved for treating vitreomacular traction in the E.U.

Novel CETP inhibitors patented at Merck & Co.

GlaxoSmithKline presents new FAS inhibitors

Merck & Co. announces novel beta-secretase inhibitors

Chinese investigators divulge new cancer therapies

Novel serotonin 5-HT transporter inhibitors disclosed by Danish group

Gelna Biopharma acquires U.S. rights to Abstral

Intravesical imiquimod found safe and feasible as intravesical therapy for bladder cancer

R-Tech Ueno begins enrollment in phase III study of unoprostone for retinitis pigmentosa

Merck KGaA and Nordic Bioscience form alliance to develop treatment for osteoarthritis of the knee

BIIB-037 well tolerated in patients with Alzheimer's disease

Harvard's Wyss Institute and Sony DADC enter collaboration for Organs-on-Chips technologies

OphthaliX completes patient enrollment for international phase III trial in dry eye syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...